Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30529025 | 1.00 | CHRNB2 (0.32) | CHRNB2CHRNA4MEN1KMT2ACASR | |
| SCHEMBL10165008 | 0.83 | CHRNB2 (0.33) | CHRNB2CHRNA4 | |
| SCHEMBL3509045 | 0.81 | MEN1 (0.32) | MEN1KMT2APGR | |
| SCHEMBL25373196 | 0.79 | — | — | |
| SCHEMBL3509516 | 0.78 | AR (0.33) | MEN1KMT2APGR | |
| SCHEMBL16256879 | 0.77 | CYP11B1 (0.37) | CHRNB2CHRNA4KMT2A | |
| SCHEMBL1433388 | 0.75 | KDM4E (0.36) | — | |
| SCHEMBL3508448 | 0.75 | CD274 (0.37) | MEN1KMT2A | |
| SCHEMBL27029963 | 0.71 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL16198399 | 0.71 | CCR1 (0.34) | MEN1KMT2ACASRPGRSSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681883-B1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-111094278-B | Diphenyl derivative and use thereof | 诺华股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-3681883-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2020-07-22 | — | — | EP | disclosed |
| CN-111094278-A | Diphenyl derivatives and their use | 诺华股份有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | NOVARTIS AG (CH) | 2020-04-28 | — | — | US | disclosed |
| WO-2019053090-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-03-21 | — | — | WO | disclosed |
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-03-14 | — | — | US | disclosed |
| EP-2278969-B1 | Inhibitors of Janus kinases | MERCK SHARP & DOHME (US) | 2013-02-13 | — | — | EP | disclosed |
| EP-2278969-B1 | Inhibitors of Janus kinases | MERCK SHARP & DOHME (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8367706-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110166129-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-07-07 | — | — | US | disclosed |
| EP-2278969-A2 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2010011375-A2 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011375-A2 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | MYOF, NGF, MUSK | CHRNB2 2975/4885CHRNA4 4542/4885MEN1 4366/4885 |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | CHRNB2 4879/4885CHRNA4 4856/4885MEN1 989/4885 |
| US-20110166129-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | CHRNB2 4879/4885CHRNA4 4855/4885MEN1 928/4885 |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | MYOF, NGF, MUSK | CHRNB2 2975/4885CHRNA4 4542/4885MEN1 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.